Ann: BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS, page-183

BIOTRON OVERVIEW

As we'll have a lot of fresh eyes on BIT now, I thought I'd give quick overview, starting with their COVID work.

Biotron turned their attention to SARS1 from HIV back in 2003 when that virus first appeared, and discovered that the E protein, one of the four structural proteins of all corona virus - S, M, N, E - is a viroporin. Unlike vaccines today that aim at the S - Spilke Protein - Biotron's BIT225 compound works against E - Envelope - of SARS-COV-2 and the corresponding Vpu viroporin of HIV. The difference in this approach may prove significant. The Spike protein is what SARS2 uses to attach itself to human cells at our ACE-2 receptor cells, and our immune system is primed to ward off S after vaccination, which of course wanes over a short period. Also, vaccines provide little other health benefit against C19, which therefore makes vaccines valid for those with strong immune systems and without comorbidities only, but not in all cases; some very healthy people also become severely sick from C19. Lastly, S mutates rapidly that leads to new variants, which will require constant vaccine alterations, like with influenza vaccines.

The E protein on the otherhand is highly contained across all corona viruses and has only changed by four amino acids since SARS1. This totally elliminates, or gretaly reduces the risks caused by mutations. This fact cannot be overstated. The E Protein plays a major role in viral replication, As a voroporin it enables the movement of cells through a pathway into host cells, a critical step in replication. Back in 2003 Biotron managed to close this pathway, and in doing so first demonstrate that E is in fact a viroporin. Once SARS1 was contained with nine months due to two simple facts; patients were symptomatic - unlike with C19 infections - which enables the need for quarantining to be easily recognized, and secondly because the fatality rate form SAR1 was 12%, dangerously high for the virues own sake as it too easily killed it hosts, Biotron then turned their attention back to HIV and other diseases.

The recent results from Biotron for SARS2 are simply oustanding, and will very quickly lead to an emergency use treatment trial in the US as a phase 2/3 level. This is possible due to the very high safety profile that BIT225 has and the many instances of its use so far in HIV trials. I expect further news on this before years end. Yes, that quick !

A human trial will also begin outside of the USA, possibly here in Australia, and likewise, new will flow vey quickly.

The fourth wave of C19 is proving devastating in Europe, and as expeceted, is proving to show that this pandemic is becomeing one of the unvaccinated, just as 96% of ICU cases in Australia and other OECD countries are those unvaccinated. This is tragic, but bodes well for new drug development.

Biotrons is far advanced in viroporin inhibitor drug development, and there are no equals that have demonstrated the same results on E. As such, it is my view that this technology is going to have every assistance in the world thrown at it asap.

You know what that means.

Need to cut this short, but hope to manage more on the weekend.